<p>Alpha Tau Medical Ltd.（纳斯达克代码：DRTS - 获取免费报告）在周一的交易中股价创下 52 周新高。该股最高交易价格为 9.90 美元，最后交易价格为 9.9750 美元，成交量为 1,997,160 股。该股此前收盘价为 8.51 美元。</p>
<p>获取 <strong>Alpha Tau Medical</strong> 的提醒：</p>
<h2>华尔街分析师观点</h2>
<p>几家研究公司对 DRTS 进行了评论。Piper Sandler 在 3 月 4 日的研究报告中重申了对 Alpha Tau Medical 的 “中性” 评级，并设定了 5.00 美元的目标价。HC Wainwright 在 3 月 10 日的研究报告中重申了对 Alpha Tau Medical 的 “买入” 评级，并设定了 12.00 美元的目标价。花旗集团在 3 月 11 日的研究报告中将 Alpha Tau Medical 的目标价从 7.00 美元上调至 9.00 美元，并给予该公司 “买入” 评级。Weiss Ratings 在 4 月 20 日的研究报告中重申了对 Alpha Tau Medical 的 “卖出（d-）” 评级。最后，Zacks Research 在 2 月 17 日的研究报告中将 Alpha Tau Medical 的评级从 “强烈卖出” 上调至 “持有”。两位股票研究分析师给予该股 “买入” 评级，两位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，Alpha Tau Medical 目前的共识评级为 “持有”，平均目标价为 8.67 美元。</p>
<p><strong>查看我们对 Alpha Tau Medical 的最新分析</strong></p>
<h2>Alpha Tau Medical 股价上涨 19.8%</h2>
<p>该公司 50 日简单移动平均线为 7.38 美元，200 日简单移动平均线为 6.10 美元。该股市值为 8.9735 亿美元，市盈率为-19.28，贝塔值为 1.11。该公司的债务与股本比率为 0.08，速动比率为 7.45，流动比率为 7.45。</p>
<p>Alpha Tau Medical（纳斯达克代码：DRTS - 获取免费报告）最近在 3 月 9 日公布了其财报。该公司报告季度每股收益为（0.14 美元），低于分析师共识预期的（0.13 美元）0.01 美元。整体来看，股票分析师预计 Alpha Tau Medical Ltd.在本年度将发布-0.5 美元的每股收益。</p>
<h2>机构资金流入和流出</h2>
<p>几家大型投资者最近对该公司的持仓进行了调整。Mariner LLC 在第四季度将其在 Alpha Tau Medical 的持仓增加了 1.6%。Mariner LLC 目前拥有 125,165 股该公司的股票，价值 620,000 美元，此前在该期间又购买了 1,915 股。Trifecta Capital Advisors LLC 在第四季度购买了 Alpha Tau Medical 的新头寸，价值 48,000 美元。Levin Capital Strategies L.P.在第三季度将其在 Alpha Tau Medical 的持仓增加了 6.3%。Levin Capital Strategies L.P.目前拥有 204,714 股该公司的股票，价值 923,000 美元，此前在该期间又购买了 12,200 股。Envestnet Asset Management Inc.在第三季度购买了 Alpha Tau Medical 的新头寸，价值 62,000 美元。最后，Wells Fargo &amp; Company MN 在第四季度将其在 Alpha Tau Medical 的持仓增加了 291.7%。Wells Fargo &amp; Company MN 目前拥有 23,500 股该公司的股票，价值 116,000 美元，此前在该期间又购买了 17,500 股。2.65% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>Alpha Tau Medical 公司简介</h2>
<p>（获取免费报告）</p>
<p>Alpha Tau Medical Ltd.是一家总部位于以色列内斯齐奥纳的医疗技术公司，专注于开发针对实体肿瘤的靶向α辐射疗法。该公司的核心创新，称为扩散α发射体辐射疗法（DaRT），利用短寿命放射性同位素将高能α粒子直接输送到肿瘤组织内或相邻区域。通过利用α辐射的强大细胞毒性效应，Alpha Tau Medical 旨在提供一种新颖的近距离放射治疗方法，可能克服放射抗性并保护周围健康组织。</p>
<p>该公司的主打产品 Alpha DaRT 目前正在临床研究中评估，适用于复发性或转移性头颈癌、皮肤癌和其他实体肿瘤等多种适应症。</p>
<h2>推荐故事</h2>
<ul>
<li>我们更看好的五只股票，胜过 Alpha Tau Medical</li>
<li>MercadoLibre 大胆投资增长：折扣加深</li>
<li>AI 分红增加：三只巨头股票提升分红</li>
<li>疯狂的 Monday.com：这家 SaaS 领军企业的反弹只是开始</li>
<li>5 只有望受益于 AI 推理热潮的股票</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Alpha Tau Medical 吗？</h2>
<p>在考虑投资 Alpha Tau Medical 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已经识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Alpha Tau Medical 并不在名单上。</p>
<p>虽然 Alpha Tau Medical 目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

DRTS

<p>Alpha Tau Medical (NASDAQ:DRTS) 的股票达到新的 52 周高点 9.90 美元，收盘价为 9.9750 美元，交易量为 1,997,160 股。分析师的评级各不相同：Piper Sandler 维持 “中性” 评级，目标价为 5.00 美元，而 HC Wainwright 则给予 “买入” 评级，目标价为 12.00 美元。该公司的市值为 8.9735 亿美元，市盈率为-19.28。公司专注于针对实体肿瘤的靶向α辐射疗法，其主要产品 Alpha DaRT 正在进行多种癌症的临床研究</p>

<p>Alpha Tau Medical Ltd. (NASDAQ:DRTS - Get Free Report) shares reached a new 52-week high during trading on Monday . The stock traded as high as $9.90 and last traded at $9.9750, with a volume of 1997160 shares changing hands. The stock had previously closed at $8.51.</p>
<div class="lb-trans"><p>Alpha Tau Medical Ltd.（纳斯达克代码：DRTS - 获取免费报告）在周一的交易中股价创下 52 周新高。该股最高交易价格为 9.90 美元，最后交易价格为 9.9750 美元，成交量为 1,997,160 股。该股此前收盘价为 8.51 美元。</p>
</div><p>Get <strong>Alpha Tau Medical</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Alpha Tau Medical</strong> 的提醒：</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>Several research firms have commented on DRTS. Piper Sandler reaffirmed a &#34;neutral&#34; rating and set a $5.00 price objective on shares of Alpha Tau Medical in a research note on Wednesday, March 4th. HC Wainwright reaffirmed a &#34;buy&#34; rating and set a $12.00 price objective on shares of Alpha Tau Medical in a research note on Tuesday, March 10th. Citigroup upped their price objective on Alpha Tau Medical from $7.00 to $9.00 and gave the company a &#34;buy&#34; rating in a research note on Wednesday, March 11th. Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Alpha Tau Medical in a research note on Monday, April 20th. Finally, Zacks Research upgraded Alpha Tau Medical from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a research report on Tuesday, February 17th. Two equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Alpha Tau Medical presently has a consensus rating of &#34;Hold&#34; and an average target price of $8.67.</p>
<div class="lb-trans"><p>几家研究公司对 DRTS 进行了评论。Piper Sandler 在 3 月 4 日的研究报告中重申了对 Alpha Tau Medical 的 “中性” 评级，并设定了 5.00 美元的目标价。HC Wainwright 在 3 月 10 日的研究报告中重申了对 Alpha Tau Medical 的 “买入” 评级，并设定了 12.00 美元的目标价。花旗集团在 3 月 11 日的研究报告中将 Alpha Tau Medical 的目标价从 7.00 美元上调至 9.00 美元，并给予该公司 “买入” 评级。Weiss Ratings 在 4 月 20 日的研究报告中重申了对 Alpha Tau Medical 的 “卖出（d-）” 评级。最后，Zacks Research 在 2 月 17 日的研究报告中将 Alpha Tau Medical 的评级从 “强烈卖出” 上调至 “持有”。两位股票研究分析师给予该股 “买入” 评级，两位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，Alpha Tau Medical 目前的共识评级为 “持有”，平均目标价为 8.67 美元。</p>
</div><p><strong>View Our Latest Analysis on Alpha Tau Medical</strong></p>
<div class="lb-trans"><p><strong>查看我们对 Alpha Tau Medical 的最新分析</strong></p>
</div><h2>Alpha Tau Medical Trading Up 19.8%</h2>
<div class="lb-trans"><h2>Alpha Tau Medical 股价上涨 19.8%</h2>
</div><p>The business has a fifty day simple moving average of $7.38 and a 200 day simple moving average of $6.10. The stock has a market cap of $897.35 million, a price-to-earnings ratio of -19.28 and a beta of 1.11. The company has a debt-to-equity ratio of 0.08, a quick ratio of 7.45 and a current ratio of 7.45.</p>
<div class="lb-trans"><p>该公司 50 日简单移动平均线为 7.38 美元，200 日简单移动平均线为 6.10 美元。该股市值为 8.9735 亿美元，市盈率为-19.28，贝塔值为 1.11。该公司的债务与股本比率为 0.08，速动比率为 7.45，流动比率为 7.45。</p>
</div><p>Alpha Tau Medical (NASDAQ:DRTS - Get Free Report) last announced its earnings results on Monday, March 9th. The company reported ($0.14) EPS for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.01). As a group, equities analysts anticipate that Alpha Tau Medical Ltd. will post -0.5 EPS for the current year.</p>
<div class="lb-trans"><p>Alpha Tau Medical（纳斯达克代码：DRTS - 获取免费报告）最近在 3 月 9 日公布了其财报。该公司报告季度每股收益为（0.14 美元），低于分析师共识预期的（0.13 美元）0.01 美元。整体来看，股票分析师预计 Alpha Tau Medical Ltd.在本年度将发布-0.5 美元的每股收益。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Several large investors have recently made changes to their positions in the company. Mariner LLC raised its position in shares of Alpha Tau Medical by 1.6% in the 4th quarter. Mariner LLC now owns 125,165 shares of the company's stock worth $620,000 after buying an additional 1,915 shares during the period. Trifecta Capital Advisors LLC purchased a new position in shares of Alpha Tau Medical in the 4th quarter worth $48,000. Levin Capital Strategies L.P. raised its position in shares of Alpha Tau Medical by 6.3% in the 3rd quarter. Levin Capital Strategies L.P. now owns 204,714 shares of the company's stock worth $923,000 after buying an additional 12,200 shares during the period. Envestnet Asset Management Inc. purchased a new position in shares of Alpha Tau Medical in the 3rd quarter worth $62,000. Finally, Wells Fargo &amp; Company MN raised its position in shares of Alpha Tau Medical by 291.7% in the 4th quarter. Wells Fargo &amp; Company MN now owns 23,500 shares of the company's stock worth $116,000 after buying an additional 17,500 shares during the period. 2.65% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>几家大型投资者最近对该公司的持仓进行了调整。Mariner LLC 在第四季度将其在 Alpha Tau Medical 的持仓增加了 1.6%。Mariner LLC 目前拥有 125,165 股该公司的股票，价值 620,000 美元，此前在该期间又购买了 1,915 股。Trifecta Capital Advisors LLC 在第四季度购买了 Alpha Tau Medical 的新头寸，价值 48,000 美元。Levin Capital Strategies L.P.在第三季度将其在 Alpha Tau Medical 的持仓增加了 6.3%。Levin Capital Strategies L.P.目前拥有 204,714 股该公司的股票，价值 923,000 美元，此前在该期间又购买了 12,200 股。Envestnet Asset Management Inc.在第三季度购买了 Alpha Tau Medical 的新头寸，价值 62,000 美元。最后，Wells Fargo &amp; Company MN 在第四季度将其在 Alpha Tau Medical 的持仓增加了 291.7%。Wells Fargo &amp; Company MN 目前拥有 23,500 股该公司的股票，价值 116,000 美元，此前在该期间又购买了 17,500 股。2.65% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Alpha Tau Medical Company Profile</h2>
<div class="lb-trans"><h2>Alpha Tau Medical 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company's core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.</p>
<div class="lb-trans"><p>Alpha Tau Medical Ltd.是一家总部位于以色列内斯齐奥纳的医疗技术公司，专注于开发针对实体肿瘤的靶向α辐射疗法。该公司的核心创新，称为扩散α发射体辐射疗法（DaRT），利用短寿命放射性同位素将高能α粒子直接输送到肿瘤组织内或相邻区域。通过利用α辐射的强大细胞毒性效应，Alpha Tau Medical 旨在提供一种新颖的近距离放射治疗方法，可能克服放射抗性并保护周围健康组织。</p>
</div><p>The company's lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.</p>
<div class="lb-trans"><p>该公司的主打产品 Alpha DaRT 目前正在临床研究中评估，适用于复发性或转移性头颈癌、皮肤癌和其他实体肿瘤等多种适应症。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Alpha Tau Medical</li>
<li>MercadoLibre Boldly Invests in Growth: Discount Deepens</li>
<li>AI Dividend Increases: 3 Massive Winners Boosting Payouts</li>
<li>Manic Monday.com: The Rally Is Just the Beginning for this SaaS Leader</li>
<li>5 Stocks Positioned to Benefit From the AI Inference Boom</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Alpha Tau Medical</li>
<li>MercadoLibre 大胆投资增长：折扣加深</li>
<li>AI 分红增加：三只巨头股票提升分红</li>
<li>疯狂的 Monday.com：这家 SaaS 领军企业的反弹只是开始</li>
<li>5 只有望受益于 AI 推理热潮的股票</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Alpha Tau Medical Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Alpha Tau Medical 吗？</h2>
</div><p>Before you consider Alpha Tau Medical, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑投资 Alpha Tau Medical 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alpha Tau Medical wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已经识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Alpha Tau Medical 并不在名单上。</p>
</div><p>While Alpha Tau Medical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Alpha Tau Medical 目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Alpha Tau Medical (NASDAQ:DRTS) Sets New 52-Week High  - Time to Buy?

Market Beat

Alpha Tau Medical

Piper Sandler Cos

Alliance HC

REPUBLIC HC

Hancock Whitney

Nano Labs

花旗

Weis Markets

卡尔蔡司

NEUBERGER BERMAN REAL ES-W/I

Zacks Quality International ETF

Zacks Focus Growth ETF

Zacks Small/Mid Cap ETF

Gulf Marine Services PLC

Vision Marine Tech

RanMarine Technology B.V.

Logan Capital Broad Inno Growth ETF

Trinity Capital

Brown Advisory US Smaller Companies PLC GBP

Levi Strauss

Atom Livin Tech Co., Ltd.

Sun Capital Management Corp.

Eneti

Enovix

Investar控股

富国银行

拉美商业服务

美国股票 MarketBeta ETF - Goldman Sachs

GS MarketBeta Intl Equity ETF

MarketWise

ALPHA TAU MEDICAL LTD C/WTS (TO PUR COM)

Hancock Whitney Pref Share HWCPZ 6.25 06/15/60

CITIGROUP INC 6.250 NON CUM SER II PFD WI

Trinity Capital Pref Share TRINL 7 01/16/25

TRINITY CAPITAL INC 7.875% NTS 30/09/2029

TRINITY CAPITAL INC 7.875% NOTES DUE 2029

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

Alpha Tau Medical（NASDAQ:DRTS）创下 52 周新高 - 现在是买入的好时机吗？